CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 101 enrolled
Drug / intervention
FTC/TDF (Truvada®)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01769469
NCT01769469N/ACompleted
CompareCT.gov

Renal, Endocrine, and Bone Changes in Response to Treatment With Coformulated Emtricitabine-Tenofovir for Pre-Exposure HIV Prophylaxis (PrEP) in HIV Uninfected Young Men Who Have Sex With Men.

University of North Carolina, Chapel Hill·observational·Posted Jan 16, 2013·Updated Mar 27, 2019

In Brief

An observational study evaluating FTC/TDF (Truvada®) for HIV Infection. Completed, enrolled 101 participants across 12 sites.

Detailed Summary

This is a prospective observational cohort sub-study of subjects enrolled in the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 110 (NCT01772823) or ATN 113 (NCT01769456), which is a prospective interventional trial.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 16, 2013
Enrollment StartNov 1, 2012
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 13.5 years ago

Interventions

FTC/TDF (Truvada®)drug

There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.